Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.
Travere Therapeutics, Inc. reports developments in rare-disease biopharmaceuticals, with recurring updates on FILSPARI (sparsentan), FDA regulatory actions, commercialization in IgA nephropathy and focal segmental glomerulosclerosis, and financial results. The company focuses on therapies for rare kidney, liver, and metabolic diseases, including sparsentan and the investigational enzyme replacement therapy pegtibatinase.
Company news also covers clinical data presentations, partner-related regulatory and commercial milestones for sparsentan, capital-structure activity, inducement equity grants under Nasdaq rules, and investor-conference participation.
Travere Therapeutics (NASDAQ: TVTX) will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 4:00 p.m. ET.
According to Travere Therapeutics, the presentation will be available via live webcast on the company investor site, with a replay accessible for up to 30 days.
Travere Therapeutics (Nasdaq: TVTX) said the FDA extended review of its supplemental NDA for FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS), setting a new PDUFA target action date of April 13, 2026.
The FDA deemed Travere's recent responses to requests for further characterization of clinical benefit a Major Amendment, which triggered the extension. No additional safety or manufacturing information was requested. Travere says commercial launch preparations continue in parallel. FILSPARI is already approved by the FDA and EMA for slowing kidney function decline in adults with IgA nephropathy.
Travere Therapeutics (NASDAQ: TVTX) reported preliminary, unaudited results and 2026 outlook. The company expects Q4 2025 U.S. net product sales ≈ $127M and FY2025 U.S. net product sales ≈ $410M, with year-end cash, equivalents and marketable securities of ≈ $323M. FILSPARI reached 908 new patient start forms in Q4 and delivered ~$103M of U.S. net sales in the quarter (+108% YoY). PDUFA for FILSPARI in FSGS is Jan 13, 2026 (sNDA under FDA review). The pivotal Phase 3 HARMONY study for pegtibatinase is on track to restart in 1Q 2026.
Travere Therapeutics (NASDAQ: TVTX) announced that Eric Dube, Ph.D., president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 4:30 p.m. PT. A live webcast will be available on Travere's investor site at ir.travere.com/events-presentations, and a replay will be accessible for up to 30 days after the event.
Travere Therapeutics (NASDAQ: TVTX) announced on December 10, 2025 that its Compensation Committee granted inducement equity awards to five new employees totaling 20,300 restricted stock units (RSUs).
The RSUs were granted outside the 2018 Equity Incentive Plan as inducements under Nasdaq Listing Rule 5635(c)(4). The awards vest over four years with 25% vesting each anniversary, subject to continued service through each vesting date.
Travere Therapeutics (NASDAQ: TVTX) announced that on November 10, 2025 its Compensation Committee granted inducement restricted stock units to three new employees totaling 25,700 RSUs. The grants were made outside the company’s 2018 Equity Incentive Plan but subject to its terms as permitted under Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years with 25% vesting on each anniversary of the grant date, subject to continued service through each vesting date.
Travere Therapeutics (Nasdaq: TVTX) presented late-breaking Phase 3 DUPLEX data at ASN Kidney Week 2025 (Nov 6-9). The analyses show FILSPARI (sparsentan) patients were more likely to reach urine protein-to-creatinine ratio (UPCR) below 0.7 g/g versus maximum labeled dose irbesartan (37.5% vs 21.4%, RR 1.8).
At week 108, rates were 19% vs 11.2% (RR 1.7). DUPLEX-aligned RaDaR modeling linked achieving UPCR0.7 g/g at 24 months to markedly lower five-year kidney-failure risk (HR 0.14); applying a 26% relative UPCR reduction for FILSPARI translated to a modeled (HR 0.76).
Travere Therapeutics (NASDAQ: TVTX) said company management will participate in multiple investor conferences in November–December 2025, including Guggenheim Healthcare (Nov 11, 2025 at 9:00 a.m. ET), Stifel Healthcare (Nov 12, 2025), TD Cowen Immunology & Inflammation (Nov 13, 2025 at 4:00 p.m. ET), Jefferies Global Healthcare (Nov 18, 2025 at 3:00 p.m. GMT / 10:00 a.m. ET), Evercore Healthcare (Dec 2, 2025 at 10:50 a.m. ET) and Piper Sandler Healthcare (Dec 3, 2025).
Live webcasts of presentations will be available on the company investor page at ir.travere.com/events-and-presentations, with replays accessible for up to 30 days after each event.
Travere Therapeutics (NASDAQ: TVTX) reported 3Q 2025 total revenue of $164.9 million, which included a $40.0 million market access milestone and license revenue. The company reported a $25.7 million net income for 3Q 2025 (or $0.29 per basic share) versus a net loss in the year-ago quarter and held $254.5 million in cash, cash equivalents and marketable securities as of Sept 30, 2025. FILSPARI commercial momentum continued: the release cites 155% year-over-year U.S. growth and program updates ahead of a PDUFA target action date of Jan 13, 2026 for FSGS. The company also repaid roughly $68.9 million of 2025 convertible notes and reported progress on pegtibatinase development and global partnerships.
Travere Therapeutics (NASDAQ: TVTX) will report third quarter 2025 financial results on Thursday, October 30, 2025 after market close.
The company will host a conference call and webcast to discuss results and provide a business update at 4:30 p.m. ET. Webcast and dial-in details are available on Travere's Investor Events page, and an archived recording will be available for 30 days after the live event.